果冻传媒

Live
UPDATED ON 30 JANUARY 2026
News

AstraZeneca & Experian: Markets live blog

News and updates on your investments
漏 Investors鈥 Chronicle
Highlighted
January 30
AstraZeneca expands into weight loss with China deal

AstraZeneca (AZN) has struck a wide-ranging obesity and type 2 diabetes deal with China鈥檚 CSPC Pharmaceuticals (HK:1090).

The pharma giant will pay CSPC $1.2bn (拢870mn) upfront, with further development milestones of up to $3.5bn, plus commercial payments and royalties.  

AstraZeneca鈥檚 presence in weight loss drugs is less advanced than competitors like Eli Lilly (US: LLY) or Novo Nordisk (DK:NOVOB), but it has been building up a portfolio of next generation 鈥渋ncretin鈥 medicines that aim for better tolerability and muscle preservation. 

The obesity deal also follows AstraZeneca鈥檚 recent announcement that it plans to invest $15bn in China through to 2030 in expanding R&D, manufacturing and deals with local companies in a sign of the country鈥檚 growing importance in early-stage drug development.

The agreement also builds on a strategic research collaboration signed last year, when AstraZeneca paid $110mn to work with CSPC on AI-driven drug discovery, with more than $5bn of potential milestones attached.

January 30
Peel Hunt marked up on bullish update

Peel Hunt (PEEL) shares rose 6 per cent after the Aim-traded broker said it expects to beat market forecasts for annual revenue and profit.

In a short update, the company said it had 鈥渟upported clients on a range of M&A and equity capital markets transactions鈥 in its second half. House broker Keefe, Bruyette & Woods forecasts revenue of 拢130mn and net income of 拢11.2m for the year to March.

January 30
Experian launches surprise $1bn buyback

Experian (EXPN) caught the market off guard this morning with a $1bn (拢730mn) share buyback, a step-up from a previous pattern of smaller repurchases mainly aimed at offsetting dilution from employee share schemes.

The credit bureau and data analytics group said the programme will reduce the overall share count and cover obligations under staff share plans. It will run until no later than 30 June 2027.

Management said Experian is trading 鈥渟trongly鈥 and is set to end the financial year with a 鈥渇avourable鈥 leverage position. 鈥淕iven this flexibility, we see opportunity to drive additional shareholder value through the introduction of increased share repurchases,鈥 it added.

The shares rose 3.5 per cent to 2,788p on the news, but are still down 30 per cent over the past year on concerns that AI could squeeze its pricing power. That worry has also weighed on peers such as Relx (REL) and other data giants.

January 30
产测听Michael Fahy
Cohort order secures sales target

Cohort (CHRT) reported two new orders for subsidiary Marlborough Communications totalling 拢17.9mn, which mean that revenue consensus forecasts for its current financial year ending in April are now fully underpinned, chief executive Andy Thomis said.

Cohort鈥檚 shares rose by 3 per cent. Although 鈥渞elatively small鈥, the orders are reassuring and with the company鈥檚 shares trading at a discount to defence peers this provides 鈥渁n attractive entry point鈥, said RBC Capital Markets analyst Ben Pfannes-Varrow.

January 30
产测听Michael Fahy
Demand holds up at Avon despite shutdown

Avon Technologies (AVON) said it had enjoyed a 鈥渞ecord start鈥 to its 2026 financial year, powered by demand for its chemical, biological, radiological and nuclear (CBRN) protection products, despite a slowdown at its Team Wendy protective helmets division linked to the recent US government shutdown.

The company did not give any figures for trading for the three months to December, but chief executive Jos Sclater said it was on track to 鈥渕eet or exceed鈥 the guidance it gave when publishing full-year results in November of 鈥渉igh-single-digit鈥 revenue growth and an adjusted operating margin of between 14-16 per cent. Broker Peel Hunt expects adjusted earnings per share to grow by a third to 116.5p.